Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine
Neuropsychiatric Disease and Treatment · 2011-05 · 341
DOI: 10.2147/ndt.s10464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychiatric Disease and Treatment, 2011-05. Verfasst von Sabine Lindquist und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section Clinical Neuroimmunology and Neurochemistry, Department of Neurology, Hannover Medical School, Hannover, Germany.
Zitieren
APA
Lindquist, S., & Stangel, M. (2011). Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatric Disease and Treatment, 341. https://doi.org/10.2147/ndt.s10464
Vancouver
Lindquist S, Stangel M. Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatric Disease and Treatment. 2011:341. doi:10.2147/ndt.s10464
BibTeX
@article{Lindquist2011,
author = {Lindquist, Sabine and Stangel, Martin},
title = {Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine},
journal = {Neuropsychiatric Disease and Treatment},
year = {2011},
pages = {341},
doi = {10.2147/ndt.s10464}
}
EUVIMED